A comparison of heparin/warfarin and enoxaparin thromboprophylaxis in spinal cord injury: the Sheffield experience.
OBJECTIVE
To compare the safety and effectiveness of two different thromboprophylactic protocols in the management of patients with spinal cord injury - one using heparin/warfarin and the other using enoxaparin.


METHODS
Retrospective.


METHODS
Princess Royal Spinal Injuries Unit, Sheffield, UK.


METHODS
Retrospective review of two cohorts of patients with acute spinal injury admitted to a supra-regional spinal injuries centre and treated with different pharmacological agents. One group received heparin/warfarin in combination with antiembolism stockings and mechanical measures for thromboprophylaxis whereas the second group received enoxaparin in combination with the other measures. Patients who developed clinical symptoms suggestive of deep vein thrombosis or pulmonary embolism were investigated as appropriate.


RESULTS
Four of the 101 patients on heparin/warfarin developed symptoms of venous thromboembolism compared to 13 of the 72 who were on enoxaparin. Of the 13, three had been on 40 mg of enoxaparin daily and 10 on 20 mg enoxaparin daily. Six patients on enoxaparin and one patient on warfarin developed thromboembolic complications after they had been mobilised and the anticoagulant discontinued. Eight patients on warfarin prophylaxis and three patients on enoxaparin developed haemorrhagic complications necessitating cessation of therapy.


CONCLUSIONS
This study suggests that the traditional protocol of warfarin/heparin for thromboprophylaxis in spinal cord injury patients remains a safer option than enoxaparin.
Princess Royal Spinal Injuries Unit, Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK.
P
P
Thumbikat
P M
PM
Poonnoose
P
P
Balasubrahmaniam
G
G
Ravichandran
M R
MR
McClelland
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D002648:Child; D015331:Cohort Studies; D015897:Comorbidity; D004359:Drug Therapy, Combination; D004739:England / Q000453:epidemiology; D017984:Enoxaparin / Q000008:administration & dosage; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000453:epidemiology* / Q000517:prevention & control; D012189:Retrospective Studies; D013119:Spinal Cord Injuries / Q000453:epidemiology*; D013997:Time Factors; D020246:Venous Thrombosis / Q000453:epidemiology* / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage
D000925:Anticoagulants; D017984:Enoxaparin; D014859:Warfarin; D006493:Heparin